Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo

Cancer Research

Volumn 62, Issue 8, 2002, Pages 2390-2397

  Rabbani, Shafaat A ^a   Gladu, Julienne ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; IMMUNOGLOBULIN G; IODINE 125; MESSENGER RNA; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; UROKINASE RECEPTOR ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER MODEL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; ENZYME LOCALIZATION; FEMALE; GENE ISOLATION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IN VIVO STUDY; METASTASIS; NICK END LABELING; NONHUMAN; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL DIVISION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNOGLOBULIN G; IMMUNOTHERAPY; IODINE RADIOISOTOPES; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NECROSIS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RATS; RATS, INBRED F344; RECEPTORS, CELL SURFACE;

EID: 0037089470     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
2. Membrane and matrix localization of proteinases: A common theme in tumor cell invasion and angiogenesis
3. On the regulation of fibromolysis
4. Plasminogen activators, tissue degradation, and cancer
5. Growth factors in the regulation of pericellular proteolysis: A review
6. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type-1 inhibitor in breast cancer
7. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells
8. Structural requirements for the growth factor activity of the aminoterminal domain of urokinase
9. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo
10. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
11. Isolation and characterization of multiple isoforms of the rat urokinase in osteoblasts
12. Cellular receptor for urokinase plasminogen activator: Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
13. In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion
14. Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation
15. In vivo invasion of modified chorioallantoic membrane by tumor cells: The role of cell-surface bound urokinase
16. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis
17. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy
18. Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
19. Src-dependence and pertussis toxin sensitivity of urokinase receptor dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells
20. 3 integrin induce chemotaxis and cytoskeleton reorganization through different signalling pathways
21. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice
22. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose
23. A peptide derived from the non-receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death
24. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells
25. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)
26. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model
27. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer
28. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy
29. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer
30. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies
31. Regulation of integrin function by the urokinase receptor
32. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody
33. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model
34. Absence of host plasminogen activator inhibitor I prevents cancer invasion and vascularization
35. Urokinasereceptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo
36. The role of the plasminogen activation system in angiogenesis and metastasis